Neurocrine Bio. stock price target raised by BMO Capital to $124

Published 31/07/2025, 12:50
Neurocrine Bio. stock price target raised by BMO Capital to $124

Investing.com - BMO Capital raised its price target on Neurocrine Bio. (NASDAQ:NBIX) to $124.00 from $115.00 on Thursday, while maintaining a Market Perform rating on the stock. The company, currently valued at $13.5 billion, trades at a high earnings multiple according to InvestingPro data, with analyst targets ranging from $124 to $192.

The price target increase reflects higher projected revenues for Crenessity, following what BMO described as a strong start to the product’s launch. Crenessity beat consensus expectations by 122% in the latest financial results.

Despite the positive performance of Crenessity, BMO noted that concerns around Ingrezza’s performance in the second half of the year overshadowed the results. The company cut the top end of its Ingrezza guidance.

BMO pointed to a strong financial report from Teva, coupled with Neurocrine’s reduced guidance, as indicators of potential continued pricing headwinds from Teva’s Austedo affecting Ingrezza sales through the remainder of the year.

According to BMO, Neurocrine’s management expects stabilization in 2026, though uncertainty remains about the competitive landscape and pricing pressures in the near term.

In other recent news, Neurocrine Biosciences Inc reported strong financial results for the second quarter of 2025, surpassing analysts’ expectations. The company achieved earnings per share of $1.65, which was significantly higher than the anticipated $0.96, marking a surprise increase of 71.88%. Additionally, Neurocrine Biosciences reported revenue of $687.5 million, exceeding the forecasted $653.32 million by 5.23%. These results highlight the company’s robust performance during this period. Such financial achievements are crucial for investors as they provide insight into the company’s current financial health. The earnings beat and revenue growth are notable developments for Neurocrine Biosciences. This information follows recent analyst activity, although no specific upgrades or downgrades were mentioned. Overall, these recent developments paint a factual picture of the company’s financial standing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.